Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBG453, NIS793, and canakinumab in lower risk MDS
NCT04810611Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of sabatolimab in myelodysplastic syndrome (MDS) (5 arms), sponsored by Novartis. Primary endpoints: Dose-Limiting Toxicities at 30 months, Dose interruption reduction at 30 months and 2 more. Started Jun 2021; status: terminated.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04810611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810611.